Chemoinformaics analysis of 2,4-Dihydroxy-2H-1,4-benzoxazin-3(4H)-one
| Molecular Weight | 181.147 | nRot | 0 |
| Heavy Atom Molecular Weight | 174.091 | nRig | 12 |
| Exact Molecular Weight | 181.038 | nRing | 2 |
| Solubility: LogS | -1.097 | nHRing | 1 |
| Solubility: LogP | 0.159 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 20 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 13 | No. of Aromatic Carbocycles | 1 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 7 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 8 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 6 |
| nHA | 4 | APOL | 22.3356 |
| nHD | 2 | BPOL | 10.1964 |
| QED | 0.558 |
| Synth | 3.096 |
| Natural Product Likeliness | 1.18 |
| NR-PPAR-gamma | 0.007 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.002 |
| Pgp-sub | 0.062 |
| HIA | 0.035 |
| CACO-2 | -5.255 |
| MDCK | 0.0000194 |
| BBB | 0.966 |
| PPB | 0.102951 |
| VDSS | 0.647 |
| FU | 0.690561 |
| CYP1A2-inh | 0.229 |
| CYP1A2-sub | 0.61 |
| CYP2c19-inh | 0.042 |
| CYP2c19-sub | 0.432 |
| CYP2c9-inh | 0.021 |
| CYP2c9-sub | 0.879 |
| CYP2d6-inh | 0.003 |
| CYP2d6-sub | 0.455 |
| CYP3a4-inh | 0.008 |
| CYP3a4-sub | 0.175 |
| CL | 4.344 |
| T12 | 0.609 |
| hERG | 0.006 |
| Ames | 0.773 |
| ROA | 0.445 |
| SkinSen | 0.509 |
| Carcinogencity | 0.698 |
| EI | 0.455 |
| Respiratory | 0.216 |
| NR-Aromatase | 0.617 |
| Antiviral | No |
| Prediction | 0.875949 |